The US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee will meet October 30, 2026, to ...

Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.

Keith Warren, MD | Authors | The Eye Care Network delivers clinical news, expert interviews, and conference coverage across ophthalmology, retina, and optometry — uniting Ophthalmology Times, Modern ...

Elizabeth A. Davis MD, FACS | Authors | The Eye Care Network delivers clinical news, expert interviews, and conference coverage across ophthalmology, retina, and optometry — uniting Ophthalmology ...

EURETINA President Nicole Eter, MD, picks the sessions busy clinicians should follow at the 26th EURETINA Congress in Vienna, from durability data to AI. She also explains why early referral is still ...

David F. Chang, MD, explained how offering complementary refractive IOLs reduces patient anxiety and indecision.

Steve Swalgen is national director of lab business, Santinelli International, Hauppauge, NY. Swalgen also is an advisory board member of the Optical Laboratory Association (OLA) and has developed and ...

The course is designed for comprehensive and pediatric ophthalmologists and optometrists, who often see patients with new ...

When people ask how I define a successful premium IOL outcome, they usually expect a number. The honest answer is that a ...

Vaidehi Dedania, MD, shared what the first whole eye transplant revealed about reperfusion, retinal cells, and sight. Dedania ...

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...

MOGAD more commonly presents with bilateral optic neuritis and more disc edema at onset, Chen said, with substantial optic ...